Editorial Comment

The authors argue against use of the term favorable intermediate risk disease to describe low volume GG2 cancer based on rates of adverse pathology of about 20%, which may not be considered favorable.
Source: The Journal of Urology - Category: Urology & Nephrology Authors: Tags: Adult Urology Source Type: research